Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9NRR5
UPID:
UBQL4_HUMAN
Alternative names:
Ataxin-1 interacting ubiquitin-like protein; Ataxin-1 ubiquitin-like-interacting protein A1U; Connexin43-interacting protein of 75 kDa
Alternative UPACC:
Q9NRR5; A6ND44; B2RAY7; Q5VYA0; Q5VYA1; Q9BR98; Q9UHX4
Background:
Ubiquilin-4, known for its alternative names such as Ataxin-1 interacting ubiquitin-like protein and Connexin43-interacting protein of 75 kDa, plays a pivotal role in protein degradation. It targets misfolded or accumulated proteins for proteasomal degradation by binding polyubiquitin chains. Furthermore, Ubiquilin-4 is a key regulator in DNA repair, specifically inhibiting homologous recombination repair by promoting the degradation of MRE11, thus favoring non-homologous end joining pathways.
Therapeutic significance:
Given its involvement in amyotrophic lateral sclerosis, a neurodegenerative disorder characterized by the loss of motor neurons and presence of ubiquitin-positive inclusions, Ubiquilin-4 presents a promising target for therapeutic intervention. Understanding the role of Ubiquilin-4 could open doors to potential therapeutic strategies.